$CORT

Class action lawsuit filed against Corcept Therapeutics alleges material misstatements about relacorilant drug trials and regulatory approval prospects, covering investors from October 2024 through December 2025.

Class action lawsuit filed against $CORP alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

$CORT stock plummets 50% after FDA rejects lead drug relacorilant; class action targets alleged disclosure failures with lead plaintiff deadline April 21, 2026.

Rosen Law Firm sued Richtech Robotics for allegedly misrepresenting a Microsoft partnership. Investors must file claims by April 3, 2026.

Rosen Law Firm notifies $CORT investors of securities class action alleging misrepresentation of clinical trial data for relacorilant drug and undisclosed FDA concerns.

Rosen Law Firm files securities class action against Franklin BSP Realty Trust alleging false statements. Investors must act before lead plaintiff deadline.

Johnson Fistel investigates Corcept Therapeutics ($COPT) for securities violations after FDA rejected relacorilant application, triggering 50% stock decline.

Corcept Therapeutics faces securities class action over allegedly misleading statements about relacorilant's FDA approval prospects, triggering 50% stock plunge and $3.6B market cap loss.

Law firm Bragar Eagel & Squire files class action lawsuits against $NAVAN and $COPT alleging material misstatements, citing 60%+ and 50%+ stock declines respectively.

Schall Law Firm seeks investors in $COPT securities class action, alleging false statements about relacorilant FDA approval prospects between October 2024 and December 2025.

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.

Securities fraud class actions filed against PayPal, NuScale, Corcept, and Navan. Investors must file lead plaintiff motions by April 20-24, 2026.

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Grabar Law Office investigates shareholder claims against $CORT, $ITGR, $KD, and $MOH for alleged disclosure failures and fiduciary breaches spanning clinical trials, sales concealment, and cost trend non-disclosure.

Rosen Law Firm files securities class action against Ardent Health for alleged misrepresentations in accounts receivable and insurance reserves. March 9 deadline for lead plaintiff claims.

Law firm files securities lawsuit against $CORT alleging false statements about FDA interactions regarding relacorilant drug approval prospects.

Rosen Law Firm filed securities class action against Oracle, alleging materially false statements about AI infrastructure strategy and undisclosed capital expenditures. Affected investors urged to consult legal counsel before deadline.